Literature DB >> 9645706

Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes.

C Jux1, K Leiber, U Hügel, W Blum, C Ohlsson, G Klaus, O Mehls.   

Abstract

Growth depression as a side effect of glucocorticoid therapy in childhood is partially mediated by alterations of the somatotropic hormone axis. The mechanisms of interaction between glucocorticoids and somatotropic hormones on the cellular and molecular level are poorly understood. In an experimental model of primary cultured rat growth plate chondrocytes, basal as well as GH (40 ng/ml) or insulin-like growth factor (IGF)-I (60 ng/ml)-stimulated growth was suppressed dose dependently (10(-l2)-10(-7)M) by dexamethasone (Dexa). An IGF-I antibody specifically and dose dependently inhibited the GH- but not the basic fibroblast growth factor (bFGF)-stimulated cell proliferation. GH increased the IGF-I concentration in conditioned serum-free culture medium; this was reversed by concomitant Dexa. Dexa time dependently suppressed the transcription of GH receptor (GHR) messenger RNA (mRNA) and down-regulated the basal and GH-stimulated expression of GHR. Whereas no suppressive effect on basal type I IGF-receptor (IGFR) was observed, Dexa blocked the IGF-I induced increase of IGF binding. These results were confirmed by GHR and IGFR immunostaining. We conclude that Dexa impairs the GH-induced stimulation of local secretion and paracrine action of IGF-I and reduces the homologous increase of IGFR and GHR expression. The above experiments give further insight on the interaction between GH and glucocorticoids on the cellular and molecular level of growth plate chondrocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645706     DOI: 10.1210/endo.139.7.6099

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  28 in total

Review 1.  Bone growth mechanisms and the effects of cytotoxic drugs.

Authors:  H Robson
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

2.  Evidence from immunoneutralization and antisense studies that the inhibitory actions of glucocorticoids on growth hormone release in vitro require annexin 1 (lipocortin 1).

Authors:  A D Taylor; H C Christian; J F Morris; R J Flower; J C Buckingham
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  The impact of corticosteroids on growth and bone health.

Authors:  T Mushtaq; S F Ahmed
Journal:  Arch Dis Child       Date:  2002-08       Impact factor: 3.791

Review 4.  Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; David R Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-02       Impact factor: 3.243

5.  Zebrafish Expression Ontology of Gene Sets (ZEOGS): a tool to analyze enrichment of zebrafish anatomical terms in large gene sets.

Authors:  Sergey V Prykhozhij; Annalisa Marsico; Sebastiaan H Meijsing
Journal:  Zebrafish       Date:  2013-05-08       Impact factor: 1.985

Review 6.  Growth abnormalities in children and adolescents with juvenile idiopathic arthritis.

Authors:  Susanne Bechtold; Dominique Simon
Journal:  Rheumatol Int       Date:  2014-04-24       Impact factor: 2.631

7.  Bone age and factors affecting skeletal maturation at diagnosis of paediatric Cushing's disease.

Authors:  Shrikrishna V Acharya; Raju A Gopal; Anurag Lila; Padma S Menon; Tushar R Bandgar; Nalini S Shah
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

Review 8.  Regulation of skeletal growth and mineral acquisition by the GH/IGF-1 axis: Lessons from mouse models.

Authors:  Shoshana Yakar; Olle Isaksson
Journal:  Growth Horm IGF Res       Date:  2015-09-28       Impact factor: 2.372

Review 9.  Longitudinal growth in children following kidney transplantation: from conservative to pharmacological strategies.

Authors:  Tim Ulinski; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2006-05-10       Impact factor: 3.714

10.  Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  David R Weber; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; Leanne M Ward
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.